Imugene (ASX:IMU) share price lifts on major collaboration announcement

The clinical trial will evaluate the safety and efficacy of a combination drug treatment approach in cancer patients.

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene share price rises on collaboration announcement 
  • Merk & Co. has a market cap of US$198 billion 
  • The trial is intended to improve the outcomes for cancer patients 

The Imugene Limited (ASX: IMU) share price is marching higher in early trade. Imugene shares are up 4% even as the All Ordinaries Index (ASX: XAO) tumbles 1%.

The Imugene share price closed yesterday at 25 cents and is currently trading at 26 cents.

Below we look at the immuno-oncology company's clinical trial collaboration announcement.

What collaboration was announced?

The Imugene share price is gaining after the company reported that it's entered into a new clinical trial collaboration and supply agreement with US pharmaceutical giant Merck & Co. Inc. (NYSE: MRK), under its tradename MSD.

The collaborative trial will treat patients with HER-2 positive gastric cancer with Imugene's HER-Vaxx, combined with MSD's pembrolizumab. The trial will evaluate both the safety and efficacy of the combined treatment approach.

Commenting on the collaboration, Leslie Chong, Imugene's CEO, said:

HER-Vaxx has already shown a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer, and we look forward to further evaluating HER-Vaxx with pembrolizumab in a relapsed/refractory metastatic setting.

This collaboration with MSD is significant for our company as it provides the opportunity to optimize and enhance our formulations and utility in an additional setting in an effort to improve outcomes for more patients.

Imugene said the main goal of the study is to evaluate the safety and response rate of the combination therapy. It will also assess patients' "duration of response, progression free survival, overall survival, and biomarker evaluation".

In accordance with the agreement, Imugene will sponsor and fund the clinical study. It said this will be done from its existing budgets and resources.

In return, MSD will provide pembrolizumab for the duration of the study, which is expected to run for at least 24 months.

Imugene share price snapshot

The Imugene share price has been a stellar performer over the past 12 months, up 112%. By comparison, the All Ordinaries has gained 5% over that same time.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »